rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Electromed, Inc.

ELMD · NYSE American

Health CareMedical DevicesNot moving yet

ELMD stood above a rising 150-day average in 32 of the last 52 weekly readings, and has been out of that trend for the last 8 weeks. It is 16.7% below that average now. Medical Devices: 27% of its 181 stocks in an uptrend (−9 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 8
Industry in uptrend
27% -9 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$4.4M
Officials’ trades on record
0
Institutions holding
119 (+24)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 32 of 52 weeks.

17 Apr – 16 Oct
19%29%40%Apr 26Jun 26Jul 26Sep 26Oct 26

Medical Devices: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$5.3M$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months3
Buyers · sellers0 · 3
WhoDidSharesTraded
James L. CunniffCEO and Presidentsold7,003at $36.258 Jun 2026filed 9 Jun 2026
James L. CunniffCEO and Presidentsold1,671at $36.808 Jun 2026filed 9 Jun 2026
James L. CunniffCEO and Presidentsold1,026at $37.778 Jun 2026filed 9 Jun 2026
Bradley M. NagelChief Financial Officersold11,620at $36.344 Jun 2026filed 8 Jun 2026
Bradley M. NagelChief Financial Officersold181at $37.114 Jun 2026filed 8 Jun 2026
Kathleen SkarvanDirectorsold8,150at $34.3615 May 2026filed 19 May 2026
Kathleen SkarvanDirectorsold19,032at $35.2415 May 2026filed 19 May 2026
Kathleen SkarvanDirectorsold9,256at $36.2615 May 2026filed 19 May 2026
Kathleen SkarvanDirectorsold3,562at $37.3315 May 2026filed 19 May 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders119+24 on the quarter
New · exited32 · 7
Reported value$179.6M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
J.E. Simmons & Co., P.C.reduced · filed 15 Jul 2026483,822$20.5M-9,000−1.8%
BlackRock, Inc.added · filed 7 Aug 2026465,619$19.7M+6,774+1.5%
VANGUARD CAPITAL MANAGEMENT LLCreduced · filed 13 Aug 2026283,232$12.0M-51,796−15.5%
PUNCH & ASSOCIATES INVESTMENT MANAGEMENT, INC.reduced · filed 14 Aug 2026218,520$9.2M-6,000−2.7%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 2026217,115$9.2M+15,222+7.5%
DIMENSIONAL FUND ADVISORS LPadded · filed 11 Aug 2026180,447$7.6M+2,177+1.2%
TWO SIGMA INVESTMENTS, LPreduced · filed 14 Aug 2026167,492$7.1M-36,108−17.7%
GAMCO INVESTORS, INC. ET ALunchanged · filed 12 Aug 2026142,000$6.0M00.0%
STATE STREET CORPadded · filed 7 Aug 2026112,616$4.8M+6,253+5.9%
RENAISSANCE TECHNOLOGIES LLCreduced · filed 13 Aug 202699,704$4.2M-24,300−19.6%
31 Mar 2023 – 30 Jun 2026
2872116Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Bradley M. Nagel Company insiderChief Financial Officer · last 1 Sep 20260 · 1
James L. Cunniff Company insiderCEO and President · last 1 Sep 20262 · 1
Kathleen Skarvan Company insiderDirector · last 15 May 20268 · 6
Andrea M. Walsh Company insiderDirector · last 1 Dec 20250 · 0
Andrew Summers Company insiderDirector · last 1 Dec 20251 · 9
Gregory Fluet Company insiderDirector · last 1 Dec 20250 · 0
Joseph L. Galatowitsch Company insiderDirector · last 1 Dec 20250 · 0
Kathleen A. Tune Company insiderDirector · last 1 Dec 20250 · 0
Stan K. Erickson Company insiderDirector · last 1 Dec 20252 · 0
A. Jones Lee Company insiderDirector · last 1 Dec 20221 · 0
Christopher G. Holland Company insiderChief Commercial Officer · last 1 Jul 20220 · 0
Michelle C. Wirtz Company insiderChief Financial Officer · last 1 Jul 20220 · 0

Same industry

RCEL Avita MedicalLeading+100%
ATRC AtriCureLeading+49%
HAE HaemoneticsLeading+48%
HTFL HeartflowLeading+40%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2026 · to 30 Jun 202678.5%
Operating profit marginFY 2026 · to 30 Jun 202618.8%
Free cash flow marginFY 2026 · to 30 Jun 202611.4%
Return on capital employedFY 2026 · to 30 Jun 202625.7%
Cash conversionFY 2026 · to 30 Jun 202685.5%
Research spendFY 2026 · to 30 Jun 20261.8%
Share count trendFY 2026 · to 19 Aug 20260.0%
Cash and equivalentsFY 2026 · to 30 Jun 2026$20.4M
Free cash flowFY 2026 · to 30 Jun 2026$8.4M

Analyst forecasts

No analyst forecasts yet.